Pill combo could replace harsh chemo for High-Risk leukemia
NCT ID NCT04817241
First seen Nov 10, 2025 · Last updated May 23, 2026 · Updated 25 times
Summary
This study tests a new all-oral treatment (ASTX727 plus venetoclax) against standard IV chemotherapy for younger adults (18-65) with high-risk acute myeloid leukemia (AML) that lacks a FLT3 mutation. The goal is to see if the pill combo is safer and works as well or better. Only 5 people enrolled so far, and the study is active but not recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Montefiore Medical Center - Moses Campus
The Bronx, New York, 10467, United States
-
Montefiore Medical Center-Einstein Campus
The Bronx, New York, 10461, United States
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
-
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, 35233, United States
-
University of Virginia Cancer Center
Charlottesville, Virginia, 22908, United States
-
Vanderbilt University/Ingram Cancer Center
Nashville, Tennessee, 37232, United States
-
Yale University
New Haven, Connecticut, 06520, United States
Conditions
Explore the condition pages connected to this study.